ciglitazone has been researched along with Colorectal Neoplasms in 4 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The present study was performed to investigate the effects of the PPARgamma ligand, ciglitazone, and the involvement of PPARgamma in modulating the growth of human colorectal cancer cells." | 7.74 | Modulation of cell growth and PPARgamma expression in human colorectal cancer cell lines by ciglitazone. ( Darus, HM; Norazmi, MN; Yaacob, NS, 2008) |
| " To identify protein patterns involved in resistance to apoptosis, we studied two colorectal adenocarcinoma cell lines with different growth responses to low-molar concentrations of the thiazolidinedione Ciglitazone: HT29 cells underwent apoptosis, whereas SW480 cells increased cell number." | 3.80 | Autonomous inhibition of apoptosis correlates with responsiveness of colon carcinoma cell lines to ciglitazone. ( Baron, DM; Bayer, E; Gerner, C; Haudek-Prinz, VJ; Kaindl, U; Marian, B; Röhrl, C, 2014) |
| " The present study was performed to investigate the effects of the PPARgamma ligand, ciglitazone, and the involvement of PPARgamma in modulating the growth of human colorectal cancer cells." | 3.74 | Modulation of cell growth and PPARgamma expression in human colorectal cancer cell lines by ciglitazone. ( Darus, HM; Norazmi, MN; Yaacob, NS, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baron, DM | 2 |
| Kaindl, U | 2 |
| Haudek-Prinz, VJ | 1 |
| Bayer, E | 1 |
| Röhrl, C | 2 |
| Gerner, C | 1 |
| Marian, B | 2 |
| Yaacob, NS | 1 |
| Darus, HM | 1 |
| Norazmi, MN | 1 |
| Koneczny, I | 1 |
| Hudec, X | 1 |
| König, JS | 1 |
| Richard, CL | 1 |
| Blay, J | 1 |
4 other studies available for ciglitazone and Colorectal Neoplasms
| Article | Year |
|---|---|
Autonomous inhibition of apoptosis correlates with responsiveness of colon carcinoma cell lines to ciglitazone.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Color | 2014 |
Modulation of cell growth and PPARgamma expression in human colorectal cancer cell lines by ciglitazone.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Down-Regulation; D | 2008 |
Peroxisome-proliferator-activated receptors γ and β/δ mediate vascular endothelial growth factor production in colorectal tumor cells.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Cyclooxygenase 2; Humans; Peroxisome Proliferator-Activated | 2011 |
Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Colorectal Neoplasms; Dose-Response Relation | 2007 |